News
![3 Reasons Behind Exelixis Stock's Big Bounce](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
3 Reasons Behind Exelixis Stock's Big Bounce
After experiencing a dismal September and sliding quite a bit over the last few weeks after a rebound, Exelixis (NASDAQ: EXEL) stock enjoyed a big bounce on Thursday. The biotech announced its....
![3 Reasons It's Smart to Buy Celgene's Stock Now](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
3 Reasons It's Smart to Buy Celgene's Stock Now
Celgene Corp. (NASDAQ: CELG) shares nose-dived in October following a trial failure and third-quarter financials that failed to impress. However, there are good reasons investors ought to consider....
![The Precision Medicine Stock That's Revolutionizing Cancer Treatment](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
The Precision Medicine Stock That's Revolutionizing Cancer Treatment
Foundation Medicine's (NASDAQ: FMI) genetic screening tests are leading the way in discovering what medicines will work best in cancer patients based on their DNA. As more specialized drugs....
![The Single Biggest Reason Teva Pharmaceutical Industries Imploded and Fell 22% in October](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
The Single Biggest Reason Teva Pharmaceutical Industries Imploded and Fell 22% in October
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), a developer of branded and generic drugs and the largest generic drugmaker in the world, tumbled another 22% in October, according to data....
![Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today
Shares of clinical-stage biopharma Idera Pharmaceuticals (NASDAQ: IDRA) jumped over 11% today without any company-specific news. Why? The two leading RNA-based genetic medicine companies were....
![Here's Why bluebird bio Inc. Is Surging Again Today](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Here's Why bluebird bio Inc. Is Surging Again Today
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, are on the move for the second day in a row. Yesterday, the stock jumped in response to a....
![The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10%](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10%
Shares of Exelixis (NASDAQ: EXEL), a mid-cap drug developer with a focus on novel cancer therapies, rocketed higher by as much as 10% during Thursday's trading session after the company reported....
![What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
![Why Juno Therapeutics Shares Are Going Up 21.2% Today](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Why Juno Therapeutics Shares Are Going Up 21.2% Today
After the company released its third-quarter progress report and shared the latest data from its lead drug, JCAR017, shares of Juno Therapeutics (NASDAQ: JUNO) are shooting 21.2% higher at 2:30....
![Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today
As of 1:18 p.m. EDT on Thursday, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) are up 13.7%, while shares of its biotech peer Ionis Pharmaceuticals Inc. (NASDAQ: IONS) are down....
![Why Teva Pharmaceutical Is Crashing Today](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Why Teva Pharmaceutical Is Crashing Today
After the company provided investors with yet another disappointing update to its financial performance, shares in Teva Pharmaceutical (NYSE: TEVA) are losing 15% as of 1 p.m. EDT.It's been tough....
![Here's Why Intellia Therapeutics Sank as Much as 17.7% Today](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Here's Why Intellia Therapeutics Sank as Much as 17.7% Today
Shares of CRISPR gene-editing biopharma Intellia Therapeutics (NASDAQ: NTLA) dropped nearly 18% today after the company announced a major public share offering to increase its cash balance. The....
![Here's Why Neurocrine Biosciences Is Soaring](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Here's Why Neurocrine Biosciences Is Soaring
In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine....
![Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis
It's a great time to be a biotech focused on CAR-T (chimeric antigen receptor T-cell therapy). Juno Therapeutics (NASDAQ: JUNO) stock has soared so far in 2017, partially due to its own good....
![5 Things Pfizer's Management Just Said That You Don't Want to Miss](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE: PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results....
![Why ImmunoGen, Inc. Got Burned into ASH Today](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Why ImmunoGen, Inc. Got Burned into ASH Today
ImmunoGen (NASDAQ: IMGN) closed down 12.6% on Wednesday, following the release of abstracts for the American Society of Hematology (ASH) meeting next month.The data covers a pair of ImmunoGen's....
![Here's Why It's Oca-Liftoff for Intercept Pharmaceuticals Inc.](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Here's Why It's Oca-Liftoff for Intercept Pharmaceuticals Inc.
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT), a small-cap biotech company focused on the development of drugs to treat an assortment of liver diseases, vaulted higher by as much as 10% on....
![BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
It was a solid third quarter for BioMarin Pharmaceutical (NASDAQ: BMRN) as the biotech keeps plugging along, increasing sales of its orphan drugs while making progress on its pipeline drug....
![What's Causing Adamas Pharmaceuticals to Spike Higher Today](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
What's Causing Adamas Pharmaceuticals to Spike Higher Today
After a leading hedge fund reported it bought shares last month and in the wake of industry watcher upgrades, shares in Adamas Pharmaceuticals (NASDAQ: ADMS) rallied more than 10% higher earlier....
![Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Pfizer Inc. (NYSE: PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTOperatorContinue readingSource: Fool.com
![Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....
![Why bluebird bio Inc. Jumped Higher Today](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Why bluebird bio Inc. Jumped Higher Today
Shares of biotech bluebird bio (NASDAQ: BLUE) are up 7.3% at 12:24 p.m. EDT, having been up as much as 16.3% today, after the company disclosed data in its abstracts for the American Society of....
![3 Worst Performing Stocks in October](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
3 Worst Performing Stocks in October
Halloween has come and gone, but some stocks have been more tricks than treats. As good as October may have been for a lot of investors, some stocks got totally crushed last month.Trivago (NASDAQ:....
![Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
![Up in Smoke: This Marijuana Stock Imploded Last Week](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Up in Smoke: This Marijuana Stock Imploded Last Week
Few industries have put a wider smile on investors' faces this year than marijuana. As recently as June, the average marijuana stock was higher by more than 330% over the trailing 12-month period,....